CoLab is pleased to announce their new website on The Global Health Network is up and running. With information about CoLab projects, publications, and member centers, this website will greatly enhance the global visibility of CoLab. The site will be extremely useful for getting our message out about collaboration and the CoLab database, especially in LMICs. Please visit their website: https://pregnancycolab.tghn.org/
The Global Pregnancy Collaboration, (CoLab) was initiated in November 2010 and at that time we recruited 20 groups from around the world to participate. The first meeting of the group was in April 2011 and at that time the goals and philosophy of the CoLab were established.
The goals are three-fold. The overarching goal is to improve the health of women and their infants by facilitating research addressing adverse pregnancy outcomes. This would be accomplished by 1) facilitating access to data and biological samples for investigators worldwide, 2) by using the intellectual, data, and biological resources of the CoLab to perform large studies that could not be accomplished by any single centre, and 3) working to establish data and biological sample resources in developing countries.
Oversight of these efforts would be accomplished by the requirement that studies that utilize resources of the CoLab would be sponsored by a member group, who would be responsible for the timely completion of the project in accordance with good research practices and the Procedures of Operation of the CoLab. Further, access to samples and data would not be restricted but rather facilitated by CoLab. Thus, if an application for data or biological materials could be met by resources of CoLab centres interested in participating in the study, this would be supported by CoLab infrastructure even if this were not a majority of CoLab members. Importantly, CoLab would support access to materials and, in early years, additional infrastructure but the general analytical expenses of the study would be supported by the applicant.
The CoLab now includes 35 member centres from around the world. Data are available for more than 300,000 pregnancies and biological materials have been collected on at least 4,000 women prior to the clinically evident problems. In keeping with its mission, the group has provided data and biological materials for several ongoing studies. However, in the last year, the activities of the group have expanded. In recognition of the fact that organized information on how to perform studies related to adverse pregnancy outcomes would be beneficial to researchers for studies done worldwide, CoLab has elected to prepare “white papers” on important topics to guide and harmonise research. In the last year we have published two position papers. One describes strategies for effective placental research: Optimising sample collection for placental research. Burton GJ, Sebire NJ, Myatt L, Tannetta D, Wang YL, Sadovsky Y, Staff AC, Redman CW. Placenta 2014 Jan;35(1):9-22. The second addresses appropriate data collection for studies of pre-eclampsia, suggesting data and biological samples to be collected in minimal and optimal data sets: Strategy for standardization of preeclampsia research. Myatt L, Redman CW, Staff AC, Hansson S, Wilson ML, Laivuori H, Poston L, Roberts JM; Global Pregnancy CoLaboratory. Hypertension 2014 Jun;63(6):1293-301.
To most effectively utilize the latter data collection strategy we are developing an online database that will standardize collection of appropriate data for preeclampsia research. The eventual goal of this approach is to standardize data collected in various studies to facilitate collaboration and combination of data in future studies of pre-eclampsia and other adverse pregnancy outcomes. This will be done through an online database for investigators worldwide that can be either used online or as a stand alone using off line computers.
- Co-PIs: Shannon Bainbridge, and Brian Cox, Sponsor: Jim Roberts
Identification of molecular subclasses of preeclampsia
- PI: Mandy Bell Schmella, Sponsor: Carl Hubel
Variation in endoglin pathway genes associated with preeclampsia
- PI: Thomas Boehm, Co-I: Martin Knoefler, Sponsor: Les Myatt
Prognostic value of Diamine Oxidase (DAO) levels in Pre-eclampsia
- PI: Lucy Chappell, Co-Is: Lucilla Poston, and Hannele Laivuori
Understanding, diagnosing and predicting pregnancy outcome in women with chronic hypertension
- PI: Brandie DePaoli Taylor Sponsor: Jim Roberts
The role of placental microparticles, Toll-like receptors and inflammation in preeclampsia
- PI: Tabassum Firoz
WHO Maternal Morbidity Working Group: data on chronic hypertension, cardiac diseases, asthma, obesity, smoking, alcohol use
- PI: Sandra Founds, Sponsor: Jim Roberts
Biomarker assay development for translation of discovery-based placental mRNA candidates to serum protein concentrations in early pregnancy to predict preeclampsia
- PI: Maya Jalmby, Sponsor: Stefan Hansson
Inflammatory profiling of preeclampsia, highlighting fetal gender, parity, BMI and IUGR: a case control study
- PI: Thomas McElrath
The use of microparticle biomarkers to predict spontaneous preterm birth
- PI: Mark Santillan
The PREDICTV (PReclampsia Early Determination for Intervention, Cure, and Therapeutics by Vasopressin) Study
- PI: Sarah Schalekamp-Timmermans, Sponsor: Eric Steegers
Sex specific differences in the placental syndrome and markers of placentation
- PI: Annetine Staff, Co-Is: Chris Redman, Peter von Dadelszen, Roberta Ness, Cuilin Zhang with Samantha Benton, Orlaith Burke and Pawel Szafranski
Maternal circulating angiogenic factors and subtypes of preeclampsia
- PI: Peter von Dadelszen, Samantha Benton
Angiogenic factors in the identification of intrauterine growth restriction
- PI: Peter von Dadelszen, Ugochinyere Vivian Ukah
External validation and recalibration of the fullPIERS model (PIERS – Pre-eclampsia Integrated Estimated RiskS)
- The EMPOWER Program